Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Immune checkpoint blockade has provided a paradigm shift in cancer therapy, but the
success of this approach is very variable; therefore, biomarkers predictive of clinical efficacy …

Immune checkpoint blockade therapy has become a major weapon in fighting cancer.
Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such …

Programmed Death-1 (PD-1; CD279) is an inhibitory receptor induced in activated T cells.
PD-1 engagement by its ligands, PD-L1 and PD-L2, maintains peripheral tolerance but also …

Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

PD1 was originally discovered in 1992 as a molecule associated with activation-induced cell
death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding …

The binding of programmed death-1 (PD-1) on the surface of T cells and PD-1 ligand 1 (PD-
L1) on tumor cells can prevent the immune-killing effect of T cells on tumor cells and …

Cancer immunotherapy has significantly flourished and revolutionized the limited
conventional tumor therapies, on account of its good safety and long-term memory ability …